Dual-purpose drugs perk up sales

Various combination therapies made up 13.6 percent of the domestic drug market in 2009, representing the fastest-growing segment of that market, according to Ubist data.

Daewoong’s Olmetec Plus tablets topped 46.7 billion won in sales last year, maintaining its first rank. Novartis’s Exforge tablets came in second with 42.9 billion won, followed by Daewoong’s Albis tablets with 40.8 billion ...